)
Abeona Therapeutics (ABEO) investor relations material
Abeona Therapeutics Morgan Stanley 24th Annual Global Healthcare Conference summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Company transition and product launch
Transitioned from R&D to commercial stage after first product approval in late 2025, expanding from 80–90 to 250 employees and establishing GMP manufacturing and supply.
ZEVASKYN, an autologous cell sheet-based gene therapy for recessive dystrophic EB, launched in December 2025, offering multi-year wound healing from a single application.
Unique launch challenges include ultra-rare disease focus, 84-hour product shelf life, and need for multidisciplinary treatment centers.
Launch strategy emphasizes foundation building, site activation, and patient ambassador networks to support adoption.
Commercially treated patients often previously used VYJUVEK, highlighting ZEVASKYN’s differentiated value for large, chronic wounds.
Market landscape and differentiation
ZEVASKYN addresses a severe genetic disorder with high morbidity and mortality, offering a durable, one-time treatment compared to weekly alternatives.
Both ZEVASKYN and VYJUVEK are needed for different wound types; ZEVASKYN is suited for large, contiguous wounds.
Clinical data show up to 12 years of wound healing from a single application, supporting its unique value proposition.
Commercialization and operational learnings
Launch requires coordination among surgeons, anesthesiologists, and EB physicians at qualified centers, with each site needing to replicate clinical success.
Patient-to-patient communication and ambassador programs are key to building trust and awareness.
Initial bottlenecks vary by institution, often related to payer mix and institutional learning curves; cross-pollination of best practices is ongoing.
Leading indicators for launch momentum include number of centers, treated patients, and patient interest; 40% of the addressable market is now within reach of a qualified center.
- ZEVASKYN launch accelerates with rising revenue, broad access, and a robust pipeline of gene therapies.ABEO
H.C. Wainwright 28th Annual Global Investment Conference - Steady ZEVASKYN rollout, robust coverage, and pipeline advances set stage for strong future growth.ABEO
12th Annual Cantor Fitzgerald Global Healthcare Conference - Q2 2026 ZEVASKYN revenue up 31% to $11.4M, NTAP status secured, net loss $20.2M, cash $146.8M.ABEO
Q2 2026 - Lead cell therapy for RDEB advances toward approval, with strong clinical data and commercial readiness.ABEO
Stifel Virtual Cell Therapy Forum - All proposals passed except the advance notice provision amendment for director nominations.ABEO
AGM 2026 - ZEVASKYN achieves durable RDEB wound healing, fueling growth and pipeline expansion.ABEO
Investor presentation - Q1 2026 saw $8.7M ZEVASKYN revenue, $17.1M net loss, and a shift to oncology pipeline.ABEO
Q1 2026 - Q2 net income reached $7.4M as pz-cel BLA resubmission and launch prep advance for H2 2024.ABEO
Q2 2024 - PZ-cel nears FDA approval with Q3 2025 launch targeted and cash runway into 2026.ABEO
Q4 2024
Next Abeona Therapeutics earnings date
Next Abeona Therapeutics earnings date
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)
)
)